




FIG. 1



Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146




Figure 2

CVT-3146 and Coronary Flow Velocity

Duration of Effect:

3/17

Duration ≥ 2.5 Baseline	
Dose (n)	Mean \pm SEM
10 μg (4)	0
30 μg (4)	0
100 μg (3)	0.2 \pm 0.2 minutes
300 μg (4)	2.2 \pm 1.3 minutes
400 μg (8)	2.8 \pm 0.8 minutes
500 μg (4)	2.9 \pm 1.3 minutes

Figure 3

Time Course of APV Ratio (CVT-3146 400 μ g)





Figure 4

Time Course of Heart Rate (CVT-3146 400 µg)



Time Course of Blood Pressure (CVT-3146 400 μ g)




Figure 6


All Drug-Related Adverse Events Were Mild and Transient

Adverse Event	All Doses	
	(n = 36)	400 µg (n = 9)
chest discomfort	3	3
increased heart rate	3	1
hypotension	2	2
flushing	2	1
shortness of breath	2	0
funny taste in mouth	1	0
sensation in mouth, sinus, and chest	1	0
headache	1	0
tingling in hands	1	1
heart racing	1	1
bradycardia	1	1
lightheadedness	1	1
cough	1	0
nausea and vomiting	1	0

7/17

Figure 7

Figure 8



9/17

Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14







Figure 15



**Figure 16****Figure 17**




Figure 18